Nov 9, 2026 · Science & Research Daily Digest
Science, space, biomedicine, and climate research highlights compiled for November 9, 2026, with summaries, links, and commentary.
I. Space & Deep Space
1. NASA’s ESCAPADE twins complete powered Earth flybys and head for Mars (solar wind at Mars)
Summary:
NASA said on November 9 that both ESCAPADE (Escape and Plasma Acceleration and Dynamics Explorers) spacecraft have completed powered Earth flybys: the first finished an ~9-minute trans-Mars injection burn near 5 a.m. EST on November 7 at about 1,000 miles altitude; the second followed near 6 a.m. EST on November 9 at about 650 miles. After launch geometry left Earth and Mars poorly aligned, the probes loitered near Sun–Earth L2 before returning for the slingshot. NASA called it the first time it has used a powered Earth flyby to send spacecraft to Mars—and it executed the maneuver twice in two days. The twins now begin a ~10-month cruise, with Mars orbit insertion targeted for September 7 and 9, 2027, to study how the solar wind drives atmospheric escape at Mars.
Links:
Commentary:
Building “wait for the window” into the trajectory gives Mars atmospheric-loss science a true dual-probe, simultaneous solar-wind sample.
2. ESA’s Hera closes in on the Didymos binary for a planetary-defense “crash-site autopsy” (planetary defense)
Summary:
From about 60 km, ESA’s Hera captured a close-up of the Didymos system with its monochrome Asteroid Framing Camera: ~780-m Didymos is clear, while much of ~151-m Dimorphos remains in shadow, revealing a previously unseen Didymos hemisphere with boulders, craters, and possible grooves or ridges. NASA’s 2022 DART impact shortened Dimorphos’s orbit by about 33 minutes, but whether the strike left a crater, reshaped the body, or both still needs near-field data. Coverage on November 9 highlighted a planned November 25 release of more detailed imagery of both asteroids; Hera will later deploy CubeSats Milani and Juventas for surface/dust and internal radar studies.
Links:
- ESA — Hera’s first close-up view of Didymos asteroids
- Astronomy Now — Hera closes in on the asteroid DART impacted
Commentary:
Kinetic deflection graduates from “we changed an orbit once” to a predictable tool only if this autopsy pins down momentum transfer.
II. Biomedicine & Health
3. Cambridge: transient mRNA activating Myc and Cyclin T1 lifts post-MI heart function ~10% in mice (cardiac regeneration)
Summary:
A University of Cambridge team reports in Nature Cardiovascular Research that modified mRNA briefly and locally co-expressing Myc and Cyclin T1 can push adult cardiomyocytes to divide and repair injury after myocardial infarction in mice. Versus mock treatment, stroke volume rose by about 10%, with lasting functional gains at 28 days and 12 weeks; short-lived, localized expression produced no clear adverse effects in the animals. The authors stress that sustained global Myc activation harms the heart—the key is dose, timing, and spatial “regenerative pulse.” Larger-animal and human studies are still required; the British Heart Foundation is funding further refinement.
Links:
- University of Cambridge — Treatment promotes repair after heart attack
- Nature Cardiovascular Research — Transient modRNA Myc and cyclin T1
Commentary:
Cardiac regeneration’s hard problem is not whether cells can divide, but for how long and where—transient mRNA turns a permanent rewrite into a controllable pulse.
4. Merck: efinopegdutide Phase 2b sharply raises MASH resolution rates; data at The Liver Meeting and in The Lancet (metabolic liver disease)
Summary:
On November 9 Merck reported MK-6024-013 Phase 2b results for once-weekly subcutaneous efinopegdutide (4/7/10 mg) in adults with biopsy-confirmed MASH and stage F2–F3 fibrosis. At 52 weeks, MASH resolution without fibrosis worsening reached 56%, 63%, and 61% across doses versus 13% on placebo (all p<0.0001); fibrosis improvement of at least one stage without steatohepatitis worsening was 43%, 52%, and 34% versus 21% on placebo. About 381 participants were randomized and dosed, with an open-label semaglutide 2.4 mg reference arm; discontinuations for adverse events rose to about 11% at the highest dose. Results were presented at The Liver Meeting and published in The Lancet.
Links:
Commentary:
The MASH race is now a trade-off between dual histologic endpoints and dropout—resolution rates look strong, GI tolerability still caps the dose.
5. Lilly’s oral GLP-1 pill Foundayo (orforglipron) cuts obstructive sleep apnea severity in Phase 3 (metabolism & sleep)
Summary:
Eli Lilly on November 9 reported ATTAIN-OSA Phase 3 results (also in JAMA): in adults with moderate-to-severe OSA and obesity or overweight, once-daily oral orforglipron (Foundayo) significantly lowered the apnea–hypopnea index at 52 weeks. Without PAP therapy, AHI fell by an average of 21.1 events/hour (~43.8%) versus ~4.8 on placebo, and 31.5% reached remission or mild disease; with PAP, AHI fell by 18.3 events/hour. Sleep apnea–specific hypoxic burden also improved. Lilly plans a U.S. filing for moderate-to-severe OSA by the end of 2026; gastrointestinal events remained the most common adverse reactions.
Links:
- Eli Lilly — Foundayo reduces obstructive sleep apnea severity
- JAMA — Orforglipron for obstructive sleep apnea (ATTAIN-OSA)
Commentary:
The next obesity-drug prize is not another kilogram lost but whether nocturnal hypoxia—and cardiovascular risk—fall with it; a daily pill lowers the adherence bar again.
6. Valneva’s tetravalent Shigella vaccine S4V2 posts dual Phase 2 wins: infant immunogenicity and adult CHIM efficacy (vaccines)
Summary:
Valneva announced on November 9 positive results from two Phase 2 trials of Shigella4V2 (S4V2), described as the world’s most clinically advanced tetravalent bioconjugate shigellosis candidate. In Kenya trial S4V02, 110 nine-month-old infants showed statistically significant anti-LPS IgG rises against all four targeted serotypes versus a meningococcal control after two doses, with titers peaking after dose two and remaining above baseline at six months and a favorable safety profile. In U.S. CHIM trial S4V03 (~120 adults), two doses followed by Shigella sonnei 53G challenge met the primary endpoint with a significant cut in shigellosis incidence versus placebo. Valneva is reviewing full datasets to guide dose and schedule optimization.
Links:
- Valneva — Positive Phase 2 results for S4V2
- Fierce Biotech — Valneva LimmaTech shot reduces Shigella infection
Commentary:
Shigella vaccines long stalled on infant protection and serotype breadth—immunogenicity plus challenge efficacy together open a real path toward Phase 3 design.
III. Climate & Environment
7. WMO releases State of the Climate Update 2026 on COP31’s opening day: ~1.47°C through September, strong El Niño into 2027 (global climate)
Summary:
On November 9 in Antalya, Türkiye, the World Meteorological Organization issued its State of the Climate Update 2026 as COP31 opened. January–September 2026 global mean surface temperature was about 1.47°C (±0.13°C) above the 1850–1900 average; the past four years (2023–2026) rank as the four warmest on record, and the past 12 years are each among the warmest. El Niño has intensified since August and is expected to peak at record strength by December, with effects lasting into early 2027, likely lifting the full-year anomaly above the nine-month average. Sea level and ocean heat are at record or tenth-straight-year record levels; 2025 greenhouse-gas concentrations set new highs. The update uses data through roughly September and does not fully capture the latest El Niño impacts.
Links:
Commentary:
COP’s opening science brief is blunt: the question is no longer whether warming continues, but how a strong El Niño vents already-record ocean heat back into the atmosphere.
8. University of Victoria: regions worldwide already at ~90–94% of Paris 1.5°C-equivalent warming, converging near 2029 (regional climate)
Summary:
Researchers at UVic’s Pacific Climate Impacts Consortium and partners report in Nature Climate Change the most comprehensive assessment yet of regional land warming across IPCC AR6 regions. By the end of 2025, every region had already reached about 90–94% of the warming expected in a 1.5°C warmer world. Human-driven global land average temperature was already ~1.9°C above preindustrial; northwestern North America has reached ~3°C versus ~1.7°C in northern Central America. Land warms faster than oceans, and high northern latitudes faster than the tropics. Despite uneven magnitudes, the study estimates all regions will hit their 1.5°C-equivalent levels at roughly the same time—around 2029. UVic released the findings on November 9 amid COP31.
Links:
Commentary:
A global 1.5°C mean is not 1.5°C everywhere—policies that only watch the global average systematically undercount impacts already hitting high-latitude land communities.
9. Yale: atomic structure of methane-eating Archaea nanowires mapped for the first time (methane cycle)
Summary:
On November 9, Nikhil Malvankar’s lab at Yale’s Microbial Sciences Institute described electron-microscopy structures of hair-like protein nanowires from a near-pure Archaea strain developed with Dutch collaborators. Distinct from previously known bacterial electrical nanowires, the structures support electron transfer as the microbes break down and recycle methane compounds in oxygen-poor settings such as the deep seafloor. Related Archaea are said to process more than 80% of methane produced in the world’s oceans, a major climate sink. Published in Nature Communications, the work offers the first molecular-level view of this machinery and may inform methane-conversion technologies.
Links:
Commentary:
Methane policy often focuses on plugging sources; molecular structure opens another door—understand who eats methane on the seafloor before trying to amplify that sink.
IV. Basic Research & Interdisciplinary Science
10. HKUST: perovskite chiral multiple quantum wells extend room-temperature spin lifetime ~300× (spin optoelectronics)
Summary:
A Hong Kong University of Science and Technology team led by Prof. Lu Haipeng announced on November 9 a Nature Photonics study of perovskite chiral multiple quantum wells. Using two-step seed-assisted crystallization, they built continuously chiral, width-gradient-coupled wells from 2D to 3D phases that enable an efficient “spin cascade,” cutting interfacial spin loss. Spin polarization persists for about 5 nanoseconds at room temperature—roughly 300 times longer than conventional limits—with circularly polarized luminescence dissymmetry factors g_lum up to ~1.4×10⁻² and spin-dependent charge-transport polarization above 80%. Proof-of-concept demos include X-ray-triggered dissymmetric photopolymerization and circularly polarized light detection.
Links:
Commentary:
Spin information usually “forgets” at room temperature—stretching lifetime by two orders of magnitude is what lets quantum sensing and spin-photonic devices leave the cryostat.
11. Weizmann: DNA-programmed active matter reshapes itself and self-organizes millimetre-scale oscillations (active matter)
Summary:
On November 9, Alexandra Tayar’s lab at the Weizmann Institute of Science reported two advances: embedding DNA and a gene-expression system in microtubule networks so materials make their own molecular motors and change shape per genetic code (Nature Materials); and introducing long DNA strands into microtubule–kinesin active fluids, where flows stretch and entangle DNA into a viscoelastic network that, via delayed mechanical feedback, drives synchronized millimetre-scale oscillations (Nature Physics, published the same day). Oscillation frequency tracks system size and activity; large-scale rhythms arise in 3D bulk without chemical signalling or pre-built scaffolds.
Links:
- Weizmann USA — DNA teaches matter some new moves
- Nature Physics — Active-flow-driven DNA remodelling oscillations
Commentary:
Writing gene circuits into soft matter gives materials both energy-consuming actuators and a self-timer—soft robots and targeted delivery are watching closely.
12. Liverpool-led team solves a 40-year cell force-sensing puzzle: stretched talin can bind itself to tune adhesion (cell mechanics)
Summary:
An international team led by Professor Ben Goult at the University of Liverpool described on November 9 a PNAS study showing that the force-sensor protein talin, when unfolded as cells pull on their surroundings, exposes a region previously misread as mainly an integrin-binding site. That region instead lets talin molecules bind one another directly—a force-triggered interaction that regulates adhesion. The sequence shares properties with amyloid-forming motifs, yet cells harness it beneficially; vinculin can dismantle the assemblies, adding reversible control. The findings reframe how cells sense physical force and may inform disease mechanisms.
Links:
Commentary:
A “disease-like” molecular tendency rewritten as an adhesion switch—cell mechanics again shows that sequence logic means opposite fates in different contexts.
Today's Summary
- Space’s lead stories are ESCAPADE’s powered Earth flybys into the Mars cruise and Hera’s near-field look at the DART impact site.
- Biomedicine delivered a preclinical cardiac-regeneration advance alongside late-stage reads in MASH, oral GLP-1 sleep apnea, and a Shigella vaccine.
- Climate coverage paired COP31’s opening WMO bulletin with a regional 1.5°C progress assessment and molecular insight into methane-eating Archaea.
- Basic research spanned room-temperature spin lifetime, DNA-driven active-matter oscillations, and a new talin force-sensing mechanism.
Daily Framing:
A “flyby insertion × clinical-readout cluster × COP opening brief” day—deep-space maneuvers and planetary-defense close-ups, metabolic and infectious-disease pipelines, and the summit’s first science bulletin all hit the same news cycle.
This digest is compiled from real-time search results and is for reference only.